Robust Influenza Pipeline Features 120+ Drug Candidates with Novel Approaches to Prevention and Treatment
DelveInsight's latest report reveals over 120 companies actively developing innovative therapies for influenza, including promising candidates like Moderna's mRNA-1010 vaccine and SAB Biotherapeutics' polyclonal antibody treatment. The pipeline showcases diverse therapeutic approaches, from next-generation vaccines to broad-spectrum antivirals, addressing critical needs in influenza prevention and treatment.
© Copyright 2025. All Rights Reserved by MedPath